Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

被引：0

作者：

Amanda Lassen

Mohammad Atefi

Lidia Robert

Deborah JL Wong

Michael Cerniglia

Begonya Comin-Anduix

Antoni Ribas

机构：

[1] University of California Los Angeles (UCLA),Department of Medicine, Division of Hematology

[2] University of California Los Angeles (UCLA),Oncology, David Geffen School of Medicine

[3] University of California Los Angeles (UCLA),Department of Surgery, Division of Surgical Oncology, David Geffen School of Medicine

[4] Jonsson Comprehensive Cancer Center (JCCC),Department of Molecular and Medical Pharmacology, David Geffen School of Medicine

[5] UCLA,Department of Medicine, Division of Hematology

[6] Jonsson Comprehensive Cancer Center at UCLA,Oncology, 11

来源：

Molecular Cancer | / 13卷

关键词：

Melanoma; AKT inhibitor; Dabrafenib; Combination therapy; Drug resistance;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
Lassen, Amanda
Atefi, Mohammad
Robert, Lidia
Wong, Deborah J. L.
Cerniglia, Michael
Comin-Anduix, Begonya
Ribas, Antoni
MOLECULAR CANCER, 2014, 13
[2] New biomarkers for response/resistance to BRAF inhibitor therapy in metastatic melanoma
Pinto, Rosamaria
De Summa, Simona
Garrisi, Vito Michele
Strippoli, Sabino
Azzariti, Amalia
Guida, Gabriella
Guida, Michele
Tommasi, Stefania
JOURNAL OF TRANSLATIONAL MEDICINE, 2016, 14
[3] BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model
Perna, Daniele
Karreth, Florian A.
Rust, Alistair G.
Perez-Mancera, Pedro A.
Rashid, Mamunur
Iorio, Francesco
Alifrangis, Constantine
Arends, Mark J.
Bosenberg, Marcus W.
Bollag, Gideon
Tuveson, David A.
Adams, David J.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2015, 112 (06) : E536 - E545
[4] Overcoming BRAF Inhibitor Resistance in Melanoma
Smalley, Keiran
Fedorenko, Inna
Paraiso, Kim H.
Flach, Edward
Anderson, Alexander R.
JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 910 - 910
[5] OVERCOMING BRAF INHIBITOR RESISTANCE IN MELANOMA
Chan, Xian Yang
Brassington, Kurt
Darby, Ian A.
Piva, Terrence J.
WOUND REPAIR AND REGENERATION, 2016, 24 (06) : A26 - A26
[6] Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, Hubing
Hugo, Willy
Kong, Xiangju
Hong, Aayoung
Koya, Richard C.
Moriceau, Gatien
Chodon, Thinle
Guo, Rongqing
Johnson, Douglas B.
Dahlman, Kimberly B.
Kelley, Mark C.
Kefford, Richard F.
Chmielowski, Bartosz
Glaspy, John A.
Sosman, Jeffrey A.
van Baren, Nicolas
Long, Georgina V.
Ribas, Antoni
Lo, Roger S.
CANCER DISCOVERY, 2014, 4 (01) : 80 - 93
[7] A Novel AKT1 Mutant Amplifies an Adaptive Melanoma Response to BRAF Inhibition
Shi, Hubing
Hong, Aayoung
Kong, Xiangju
Koya, Richard C.
Song, Chunying
Moriceau, Gatien
Hugo, Willy
Yu, Clarissa C.
Ng, Charles
Chodon, Thinle
Scolyer, Richard A.
Kefford, Richard F.
Ribas, Antoni
Long, Georgina V.
Lo, Roger S.
CANCER DISCOVERY, 2014, 4 (01) : 69 - 79
[8] The mechanism and consequences of BRAF inhibitor resistance in melanoma
Ksenia Golub
Weiyu Bai
Zhimeng Zhang
Huilin Xiao
Rongyuan Sun
Junling Shen
Jianwei Sun
Genome Instability & Disease, 2023, 4 (5) : 266 - 274
[9] AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Zuo, Qiang
Liu, Jing
Huang, Liping
Qin, Yifei
Hawley, Teresa
Seo, Claire
Merlino, Glenn
Yu, Yanlin
ONCOGENE, 2018, 37 (24) : 3275 - 3289
[10] AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma
Qiang Zuo
Jing Liu
Liping Huang
Yifei Qin
Teresa Hawley
Claire Seo
Glenn Merlino
Yanlin Yu
Oncogene, 2018, 37 : 3275 - 3289

← 1 2 3 4 5 →